Immunic’s (IMUX) “Buy” Rating Reaffirmed at D. Boral Capital

Immunic (NASDAQ:IMUX)‘s stock had its “buy” rating reiterated by D. Boral Capital in a research note issued on Tuesday,Benzinga reports. They currently have a $17.00 price target on the stock.

Other equities research analysts have also issued reports about the company. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Immunic in a report on Friday, February 21st. William Blair began coverage on Immunic in a research report on Tuesday, March 25th. They issued an “outperform” rating on the stock. Finally, StockNews.com cut shares of Immunic from a “hold” rating to a “sell” rating in a research note on Thursday, March 20th. One research analyst has rated the stock with a sell rating, seven have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $12.67.

Immunic Stock Performance

Shares of IMUX opened at $1.09 on Tuesday. The company’s 50 day moving average price is $1.09 and its 200 day moving average price is $1.21. Immunic has a 52 week low of $0.92 and a 52 week high of $2.11. The company has a market capitalization of $98.19 million, a PE ratio of -0.89 and a beta of 1.89.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Focus Partners Wealth increased its stake in shares of Immunic by 1.1% in the fourth quarter. Focus Partners Wealth now owns 2,168,353 shares of the company’s stock valued at $2,168,000 after buying an additional 23,610 shares in the last quarter. 683 Capital Management LLC lifted its stake in Immunic by 2.2% in the fourth quarter. 683 Capital Management LLC now owns 700,000 shares of the company’s stock valued at $700,000 after buying an additional 15,349 shares during the period. Millennium Management LLC boosted its stake in Immunic by 480.6% during the 4th quarter. Millennium Management LLC now owns 579,683 shares of the company’s stock worth $580,000 after acquiring an additional 479,846 shares during the last quarter. Renaissance Technologies LLC grew its holdings in Immunic by 45.6% during the fourth quarter. Renaissance Technologies LLC now owns 566,623 shares of the company’s stock valued at $567,000 after purchasing an additional 177,542 shares during the period. Finally, Bridgeway Capital Management LLC increased its stake in Immunic by 11.5% in the fourth quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company’s stock valued at $215,000 after purchasing an additional 22,200 shares in the last quarter. 51.82% of the stock is owned by institutional investors.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.